The pattern of increasing CYB561 amplification as the tumor progresses to CRPC and NEPC was also observed for PAM and genes encoding neuropeptide receptors further associating therapy resistance with the activation of neuropeptide signaling genes. This evidence concerns the gene CYB561 and neoplasm.